Akio Kanatani
Akio Kanatani, Ushiku-Shi JP
Patent application number | Description | Published |
---|---|---|
20090203710 | Novel piperidine derivative - Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X | 08-13-2009 |
20100137391 | Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder - Disclosed are: novel use of an agonist histamine receptor H3 (e.g., Imetit) for prevention of obesity or the reduction of food intake; a method for evaluation of a compound for use as a therapeutic agent targeted to histamine receptor HR protein; and a compound provided by the method. | 06-03-2010 |
20100210637 | HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE - Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: | 08-19-2010 |
Akio Kanatani, Ibaraki JP
Patent application number | Description | Published |
---|---|---|
20080200494 | Imidazopyridine Derivatives - The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R | 08-21-2008 |
20080275069 | Quinazoline Derivative - This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) | 11-06-2008 |
20090023163 | Method of Measuring Enzyme Activity and Method of Evaluating Compound - It is intended to provide a method of measuring an activity, which is a method of measuring an activity of an enzymatic reaction in which a lipid-soluble reaction product is formed by catalyzing an addition reaction of two or more kinds of substrates, characterized by comprising a labeling step in which any one of the substrates is labeled, a reaction step in which an enzymatic reaction is carried out in the presence of an enzyme, all substrates and an acceptor, and a detection step in which the reaction product is detected by bringing the labeled molecule and a molecule to be detected close to each other via the acceptor and transferring an energy generated by the labeled molecule to the molecule to be detected, and a method of evaluating a compound utilizing the method of measuring an activity. By the methods of the invention, it is possible to perform a treatment from the enzymatic reaction to the measurement of an enzyme activity with the simple steps and it is possible to provide a method of measuring an enzyme activity which can be applied to an HTS evaluation system. | 01-22-2009 |
20090029406 | Npy Y4 Agonist as Therapeutic Agent for Disease Accompanied by Intestinal Tract Dysfunction - The present invention has its object to provide an agent capable of ameliorating the intestinal tract dysfunction through a novel mechanism of action. It also has its object to provide a method for the evaluation of a compound, including the screening of the agent. A disease accompanied by intestinal tract dysfunction can be ameliorated or treated by using an NPY Y4 agonist as a therapeutic agent. A compound capable of ameliorating or treating a disease accompanied by intestinal tract dysfunction can be evaluated or screened by evaluating a compound targeting to an NPY Y4 receptor. | 01-29-2009 |
20090105136 | NPY Y2 Agonist for Use as Therapeutic Agent for Disease Accompanied by Diarrhea - An NPY Y2 agonist is used as a therapeutic agent for a disease accompanied by diarrhea. A compound capable of treating the disease can be evaluated and screened by examining the compound on the targeting to an NPY Y2 receptor. An agent capable of inhibiting the diarrhea by a novel mechanism of action; and a method for evaluation of a compound, including the screening for the agent. | 04-23-2009 |
20100184648 | Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease - A therapeutic agent for a non-alcoholic fatty liver disease comprising a melanin-concentrating hormone receptor antagonist as an active ingredient, which is developed based on a novel mechanism of action that a melanin-concentrating hormone receptor is involved in non-alcoholic fatty liver diseases. A method for screening a drug candidate compound for the treatment or prevention of a non-alcoholic fatty liver disease by utilizing the mechanism. | 07-22-2010 |
Akio Kanatani, Tsukuba-Shi JP
Patent application number | Description | Published |
---|---|---|
20090209562 | Fused ring 4-oxopyrimidine derivative - The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. | 08-20-2009 |
20100048600 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention relates to a compound of the formula (I): | 02-25-2010 |